William Blair analyst John Kreger views the FDA's "stern rebuke" of Iqvia's data quality as a "moderate public relations problem for the company." From a fundamental standpoint, the analyst does not see the "episode turning into a demand or cost problem." Iqvia's data streams are often adjusted after the fact as more information becomes available, Kreger tells investors in a research note. As such, he thinks the vast majority of the company's biopharmaceutical clients would not be surprised or alarmed by such changes in the data set. The analyst keeps an Outperform rating on the shares, viewing yesterday's developments as only a "minor fundamental risk."